Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer

• Status: Recruiting
• Trial end date: 2027-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University Medical Center
• Treatments: Lubricant Eye Drops

Criteria

Inclusion Criteria:

1. Radio-iodine therapy for thyroid cancer

2. Radioiodine therapy ≥150 mCi

3. Age 18 or older

Exclusion Criteria:

1. Use of eye drops, other than artificial tears

2. History of periocular trauma with tear duct involvement/lacrimal gland trauma

3. History of lacrimal drainage disease: canaliculitis, dacryocystitis

4. Prior radiotherapy

5. Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel)

6. Medical conditions that predispose to NLD stenosis (i.e. sarcoidosis, granulomatosis with polyangiitis, chronic lymphocytic leukemia)

7. Nasolacrimal duct obstruction at baseline